Researchers have developed nanoparticles that carry a gene-editing package specifically to the liver.
Previously, CRISPR genome editing technology was created. However, the problem with changing the genome of cells is how to do it safely, efficiently and accurately affect the organ that needs treatment.
Scientists at Tufts University and the Harvard Broad Institute and the Massachusetts Institute of Technology have developed unique nanoparticles composed of lipids – fat molecules – that can package and deliver gene-editing mechanisms specifically to the liver.
In a study, the authors showed that they can use lipid nanoparticles (LNPS) to efficiently deliver the CRISPR mechanism to the livers of mice. As a result, they can edit genome and level levels to reduce blood levels by 57%.
The problem of obesity is relevant, in particular for the United States, so the authors modified one gene that could provide a protective effect against high cholesterol levels. It inhibits the activity of other enzymes that help break down cholesterol.
The authors tested the development in mice and found that after a single injection of lipid nanoparticles, there was a decrease in cholesterol levels by 57% and triglycerides by about 29%.
This effect persisted for another 100 days.